BioImpact
VC Fund
Shinjuku, Japan
BioImpact is a VC fund in Shinjuku focused on Medical and Therapeutics. BioImpact supports the collection of information such as statistical data, and more effective information transmission centered on “research”. The company is a web production company whose business domain is the research industry. Researchers' results reports are published nationwide on a daily basis, but the impact is difficult to convey tothe world and is difficult to reach. BioImpact provides a variety of services to connect companies, researchers, centering on the four businesses of media, production, sales or sales support, and database”.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries BioImpact invests in
Stages BioImpact invests in
Countries BioImpact invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Junichi Sugihara
|
|||
Investment Focus
Industry
- Medical 1 (33%)
- Therapeutics 1 (33%)
- Biotechnology 1 (33%)
- Pharmaceutical 1 (33%)
- Information Technology 1 (33%)
Stage
- Seed 1 (33%)
- Series B 1 (33%)
Country
- Japan 1 (33%)
- United States 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Junichi Sugihara
President and CEO
|
President and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Orna Therapeutics
|
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. | $221M / Series B / Aug 16, 2022 | |
|
Orna Therapeutics
|
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. | $221M / Series B / Aug 16, 2022 | |
Inner Resource
|
Inner Resource is a cloud purchasing system specialized in research industry. | $11.3M / Seed / Feb 13, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does BioImpact invest in?
BioImpact invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Seed and Series B stage. Most of the 3 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BioImpact?
Public channels for BioImpact include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BioImpact?
The team at BioImpact includes Junichi Sugihara (President and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
